Form 8-K

8-K — CITIUS ONCOLOGY, INC.

Accession: 0001213900-26-063530

Filed: 2026-06-01

Period: 2026-06-01

CIK: 0001851484

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0292903-8k_citius.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED JUNE 1, 2026 (ea029290301ex99-1.htm)

GRAPHIC (ea029290301_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0292903-8k_citius.htm · Sequence: 1

false

0001851484

2026-06-01

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported) June 1, 2026

Citius Oncology, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

(State

or other jurisdiction of incorporation)

001-41534

99-4362660

(Commission File Number)

(IRS Employer

Identification No.)

11 Commerce Drive, 1st Floor, Cranford, NJ

07016

(Address of principal executive

offices)

(Zip Code)

Registrant’s

telephone number, including area code (908) 967-6677

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock

CTOR

The Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

8.01 Other Events.

June 1, 2026, Citius Oncology, Inc. issued a press release announcing the presentation of clinical data at the Annual Meeting of the

American Society of Clinical Oncology. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release, dated June 1, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

CITIUS ONCOLOGY, INC.

Date: June 1, 2026

/s/ Leonard

Mazur

Leonard Mazur

Chairman and Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED JUNE 1, 2026

EX-99.1

Filename: ea029290301ex99-1.htm · Sequence: 2

Exhibit

99.1

Citius

Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR®

(denileukin diftitox-cxdl) in Combination

with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Investigator-initiated

study data presented May 30, 2026, at the American Society of

Clinical

Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated

patients

20.5

months of median progression-free survival observed among 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21)

Responses

were observed in patients previously treated with immune checkpoint inhibitors,

including a 33% objective response rate in patients with

relapsed or refractory endometrial cancer

CRANFORD,

N.J., June 1, 2026 – Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused

biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq:

CTXR), today highlighted Phase 1 clinical data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual

Meeting evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in patients with recurrent or refractory

gynecologic malignancies. The poster presentation (Abstract #2564) was presented by investigators from the University of Pittsburgh

Medical Center (UPMC) Magee-Womens Hospital.

“LYMPHIR’s

ability to transiently deplete immunosuppressive regulatory T-cells may help address immune resistance in the tumor microenvironment

and enhance the effect of checkpoint inhibitors. The encouraging clinical signals and tolerability profile observed in this study support

continued clinical evaluation of this “chemo-free” immunomodulatory approach, especially in tumors where resistance to checkpoint

inhibitors remains a significant challenge,” said Dr. Myron S. Czuczman, Chief Medical Officer of Citius Oncology.

The

open-label Phase 1 study evaluated LYMPHIR in combination with pembrolizumab in 25 heavily pre-treated patients (21 evaluable for efficacy)

with recurrent or metastatic solid tumors, primarily gynecologic malignancies. Enrolled patients had received a median of five prior

therapies, and more than half had previously received anti-PD-1 or PD-L1 therapy.

Key

Efficacy and Safety findings presented at ASCO included:

● 24%

Overall Response Rate (ORR) among the 21 efficacy-evaluable patients (5 partial responses).

● Median

duration of response (mDOR) had not yet been reached because only 1 of the 5 partial responders

had progressed at the time of analysis (80% of PRs were continuing to experience clinical

benefit). The current duration of response times (time since PR was achieved) were 4.2-35

months with a median of 21.1 months.

● 33%

ORR in endometrial cancer patients previously treated with checkpoint inhibitors, including

one patient with an ongoing response greater than three years.

● 48%

of efficacy-evaluable patients (10 of 21) achieved clinical benefit, defined as complete

response (CR), partial response (PR), or durable stable disease lasting at least six months:

o Median

progression-free survival (mPFS) of 20.5 months (95% CI: 6.5 – NA) among the 10 patients

who achieved clinical benefit; overall mPFS across all 21 efficacy-evaluable patients was

5.8 months (95% CI: 2.2 – NA);

o 5

patients had a PFS of > 20 months including 1 patient with > 30 months PFS;

● Of

the 24/25 pts evaluable for dose limiting toxicities (DLTs), only 1 case of reversible Gr

3 capillary leak syndrome (CLS) was observed at the highest dose level. A maximum tolerated

dose was not achieved.

● 16

serious adverse events were observed in seven patients treated at the highest dose level.

No new safety signals or grade 3 or greater immune-related adverse events were observed.

Dr.

Alexander Olawaiye, a professor and one of the gynecologic cancer researchers at UPMC Magee-Womens Hospital and lead investigator of

the study, added, “Patients with recurrent gynecologic malignancies who progress following immunotherapy often have limited treatment

options. The clinical activity observed with denileukin diftitox-cxdl plus pembrolizumab, including durable responses and prolonged disease

control in heavily pre-treated patients, is notable. Given the lack of effective salvage treatments for these patients, especially those

that have failed prior immune-checkpoint inhibition, the novel combination of LYMPHIR plus pembrolizumab provides a potential viable

therapeutic option. Importantly, the safety profile observed was manageable in this heavily pre-treated population, supporting continued

evaluation in larger studies.”

Ongoing

translational studies are evaluating the impact of the combination on regulatory T-cells, immune effector cells, and the tumor microenvironment

to help identify potential biomarkers in order to optimize future development strategies. A Phase 2 expansion study is being planned

to further evaluate the combination in gynecologic cancers, including less heavily pre-treated and prior immunotherapy-exposed patient

populations.

About

the Study

This

open-label, dose-escalation, investigator-initiated Phase 1 study (NCT05200559), led by Dr. Alexander B Olawaiye at UPMC Magee-Womens

Hospital, enrolled 25 patients with recurrent or metastatic solid tumors who had received at least one prior line of therapy. LYMPHIR

was administered intravenously on Days 1–3 of each 21-day cycle at escalating doses (3, 6, 9, and 12 mcg/kg), along with

pembrolizumab (200 mg IV) on Day 1. Patients who completed eight cycles of combination therapy were continued on pembrolizumab

monotherapy until disease progression. Citius Oncology provided study drug and financial support to the investigator-initiated study;

the study was designed, conducted, and analyzed by the UPMC investigators.

Important

note on investigational use: The use of LYMPHIR in this study was investigational and outside of its FDA-approved indication of relapsed

or refractory Stage I–III cutaneous T-cell lymphoma. LYMPHIR is not approved by the FDA for the treatment of gynecologic malignancies

or any solid tumor, and the safety and efficacy of LYMPHIR in this setting have not been established. This Phase 1 study was not designed

or powered to evaluate clinical efficacy, and no conclusions can be drawn regarding comparative effectiveness or long-term outcomes.

Early-stage clinical data may not be predictive of results from larger or later-stage studies.

About

Gynecologic Cancers

Recurrent

or metastatic ovarian and endometrial cancers are two of the most common gynecologic malignancies in the United States. Endometrial cancer

is the most frequently diagnosed gynecologic cancer, with an estimated 70,000 new endometrial cancer cases expected in the United States

in 20261, while ovarian cancer remains the deadliest with approximately 12,700 deaths per year (51.6%) and approximately 20,000

new diagnoses each year in the United States2. These cancers are often detected at advanced stages, and although many patients

initially respond to platinum-based chemotherapy, most experience relapse and develop resistance. Survival rates in the recurrent setting

remain poor, and responses to current immunotherapies such as PD-1 inhibitors are limited, highlighting a significant unmet need for

novel treatment approaches. LYMPHIR’s transient depletion of regulatory T-cells in combination with anti-PD-1 checkpoint inhibition

may potentially enhance host anti-tumor immune responses and help overcome immunotherapy resistance in these difficult-to-treat tumors.

About

LYMPHIR (denileukin diftitox-cxdl)

LYMPHIR

is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after

at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria

toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have

entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit

protein synthesis, resulting in cell death. Denileukin diftitox-cxdl-associated anti-tumor activity is achieved via a direct cytocidal

action on IL-2R-expressing tumors and depletion of host immunosuppressive regulatory T lymphocytes (Tregs).

2021, reformulated denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral

T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize reformulated

denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved

by the FDA and subsequently launched in the U.S. in December 2025.

REFERENCES:

1. American

Cancer Society. Cancer Facts & Figures 2026 (projected). Atlanta: American

Cancer Society; 2026. https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.html

2. National

Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer

Stat Facts: Uterine and Ovarian Cancer. https://seer.cancer.gov/statfacts/html/ovary.html

About

Citius Oncology, Inc.

Citius

Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius

Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had

had at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is

growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex

technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further

support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.

Forward-Looking

Statements

This

press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and

Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future

events impacting Citius Oncology. You can identify these statements by the fact that they use words such as “will,” “anticipate,”

“estimate,” “expect,” “plan,” “should,” and “may” and other words and terms

of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject

to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors

that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds

and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully

commercialize LYMPHIR and establish a sustainable revenue stream; our ability to regain compliance with Nasdaq’s continued listing

standards; our ability to obtain, perform under and maintain third party agreements and relationships, including obtaining a new bulk

drug substance supplier; risks relating to the results of research and development activities, including those from our existing and

any new pipeline assets; early-stage clinical data may not be predictive of results from larger or later-stage studies; our ability to

secure and maintain strategic partnerships and expand international access to LYMPHIR; the estimated markets for LYMPHIR and our product

candidates and the acceptance thereof by any market; our ability to use the latest technology to support our commercialization efforts

for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics

providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure

adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related

to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability

to procure cGMP commercial-scale supply; risks related to our growth strategy; patent and intellectual property matters; government regulation;

as well as other risks described in our Securities and Exchange Commission (“SEC”) filings. These risks have been and may

be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of

future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business

are described in detail in our SEC filings which are available on the SEC’s website at www.sec.gov, including in Citius Oncology’s

Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements

speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions

to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or

circumstances on which any such statement is based, except as required by law.

LYMPHIR

(denileukin diftitox-cxdl)

INDICATION

LYMPHIR

is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL)

after at least one prior systemic therapy.

IMPORTANT

SAFETY INFORMATION

BOXED

WARNING: CAPILLARY LEAK SYNDROME

Capillary

leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs

and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.

WARNINGS

AND PRECAUTIONS

Capillary

Leak Syndrome

LYMPHIR

can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the

occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL.

These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome.

defined, CLS occurred in 27% of patients in the pooled population across 3 clinical trials, including 8% with Grade 3. There was one

(0.8%) fatal occurrence of CLS. Of the patients with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first

2 cycles of treatment. The median time to onset from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14

days (range: 2 to 40), and 75% of patients had resolution. The most common symptoms included edema, hypoalbuminemia, and hypotension.

Pleural effusion, pericardial effusion, and dehydration also occurred.

Regularly

assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum

albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated.

Withhold,

reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when

serum albumin is greater than or equal to 3 g/dL.

Visual

Impairment

LYMPHIR

can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across 3 clinical

trials, visual impairment occurred in 9%, with Grade 1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision.

Of the patients with visual impairment, 67% had resolution of their visual impairment.

Perform

baseline ophthalmic examination and monitor as clinically indicated. If patients experience symptoms of visual impairment, such as changes

in visual acuity, changes in color vision, or blurred vision, refer for ophthalmologic evaluation.

Withhold

LYMPHIR until visual impairment resolves or permanently discontinue based on severity.

Infusion-Related

Reactions

LYMPHIR

can cause serious infusion-related reactions. Infusion-related reactions were reported in 69% of patients in the pooled population across

3 clinical trials of patients who received LYMPHIR, with Grade 3 infusion-related reactions in 3.4%. Eighty-three percent of infusion-related

reactions occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever,

and arthralgia.

Premedicate

patients for the first three cycles prior to starting a LYMPHIR infusion. Monitor patients frequently during infusion. For Grade 2 or

higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles.

Interrupt

or discontinue LYMPHIR based on severity. Institute appropriate medical management.

Hepatotoxicity

LYMPHIR

can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%;

elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8

days (range: 1 to 15 days); median time to resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved.

Elevated total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%.

Monitor

liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue

LYMPHIR based on severity.

Embryo-Fetal

Toxicity

Based

on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females

of reproductive potential prior to the initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females

of reproductive potential to use effective contraception during treatment and for 7 days following the last dose of LYMPHIR.

ADVERSE

REACTIONS

The

most common adverse reactions (≥20%), including laboratory abnormalities, are increased transaminases, albumin decreased, nausea,

edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome.

USE

IN SPECIFIC POPULATIONS

Pregnancy

Risk

Summary

Based

on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. There are no available data on the use

of LYMPHIR in pregnant women to evaluate for a drug-associated risk. No animal reproductive and developmental toxicity studies have been

conducted with denileukin diftitox.

Denileukin

diftitox-cxdl causes depletion of regulatory T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy

maintenance. Advise pregnant women of the potential risk to a fetus.

the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies

are 2-4% and 15-20%, respectively.

Lactation

Risk

Summary

data are available regarding the presence of denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production.

Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR

and for 7 days after the last dose.

Females

and Males of Reproductive Potential

Based

on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman.

Pregnancy

Testing

Verify

the pregnancy status of females of reproductive potential prior to initiating LYMPHIR.

Contraception

Females

Advise

females of reproductive potential to use effective contraception during treatment with LYMPHIR and for 7 days after the last dose.

Infertility

Males

Based

on findings in rats, male fertility may be compromised by treatment with LYMPHIR. The reversibility of the effect on fertility is unknown.

Pediatric

Use

Safety

and effectiveness of LYMPHIR in pediatric patients have not been established.

Geriatric

Use

the 69 patients with Stage I-III r/r CTCL who received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%)

were 75 years of age and older. Clinical studies of LYMPHIR did not include sufficient numbers of patients 65 years of age and older

to determine whether they respond differently from younger adult patients.

You

may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Citius Oncology at

1-844-459-6744.

Please

read Important Safety Information and full Prescribing Information, including Boxed WARNING, for LYMPHIR.

Investor

Contact:

Ilanit

Allen

ir@citiuspharma.com

908-967-6677

x113

Media

Contact:

STiR-communications

Greg

Salsburg

Greg@STiR-communications.com

GRAPHIC

Filename: ea029290301_ex99-1img1.jpg · Sequence: 3

Binary file (14476 bytes)

Download ea029290301_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jun. 01, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 01, 2026

Entity File Number

001-41534

Entity Registrant Name

Citius Oncology, Inc.

Entity Central Index Key

0001851484

Entity Tax Identification Number

99-4362660

Entity Incorporation, State or Country Code

Entity Address, Address Line One

11 Commerce Drive

Entity Address, Address Line Two

1st Floor

Entity Address, City or Town

Cranford

Entity Address, State or Province

Entity Address, Postal Zip Code

07016

City Area Code

908

Local Phone Number

967-6677

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

CTOR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration